Biphenylindanone A (BINA, LS-193,571) is a research agent which acts as a potent and selective positive allosteric modulator for the group II
metabotropic glutamate receptor subtype
mGluR2.
In animal studies it showed
anxiolytic and
antipsychotic effects,[1] and blocked the effects produced by the
hallucinogenic drug
DOB. BINA and other selective mGluR2 positive modulators have therefore been suggested as a novel class of drugs for the treatment of
schizophrenia which may have superior properties to traditional antipsychotic drugs.[2]
BINA decreases cocaine
self-administration in rats, with no effect on food self-administration, and is in regard to this discrimination superior to the mGluR2/3 agonist
LY-379,268.[3]
References
^Galici R, Jones CK, Hemstapat K, Nong Y, Echemendia NG, Williams LC, et al. (July 2006). "Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice". The Journal of Pharmacology and Experimental Therapeutics. 318 (1): 173–85.
doi:
10.1124/jpet.106.102046.
PMID16608916.
S2CID14653620.
^Benneyworth MA, Xiang Z, Smith RL, Garcia EE, Conn PJ, Sanders-Bush E (August 2007). "A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis". Molecular Pharmacology. 72 (2): 477–84.
doi:
10.1124/mol.107.035170.
PMID17526600.
S2CID3097502.